Mesenchymal stem cell
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Decompensated Liver Cirrhosis
Conditions
Decompensated Liver Cirrhosis
Trial Timeline
Jul 20, 2017 → Apr 13, 2023
NCT ID
NCT03254758About Mesenchymal stem cell
Mesenchymal stem cell is a phase 1/2 stage product being developed by Rohto Pharmaceutical for Decompensated Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03254758. Target conditions include Decompensated Liver Cirrhosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04522986 | Phase 1 | Completed |
| NCT03472742 | Pre-clinical | Completed |
| NCT03254758 | Phase 1/2 | Completed |
Competing Products
5 competing products in Decompensated Liver Cirrhosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| Mesenchymal Stem Cell | Rohto Pharmaceutical | Pre-clinical | 23 |
| Aliskiren + Placebo | Novartis | Phase 3 | 77 |
| BMS-986259 | Bristol Myers Squibb | Phase 2 | 51 |
| Albutein 20% | Grifols | Phase 3 | 74 |